NCT06750783View on ClinicalTrials.gov

The Effects of Xuezhikang and Atorvastatin on Lipid in Patients With Dyslipidemia and Prediabetes

PHASE4RecruitingINTERVENTIONAL
Enrollment

398

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Prediabetic State (IGT)
Interventions
DRUG

Xuezhikang

The Xuezhikang group takes Xuezhikang at a dose of 600 milligrams twice a day, orally after meals;

DRUG

Atorvastatin

The atorvastatin group takes atorvastatin 20mg once a day, orally after meals.

Trial Locations (3)

102209

RECRUITING

Beiqijia Community Health Service Center, Changping District, Beijing, Beijing

102218

RECRUITING

Beijing Tsinghua Changgung Hospital, Beijing

Unknown

RECRUITING

Xiaotangshan Community Health Service Center, Changping District, Beijing, Beijing

All Listed Sponsors
lead

Beijing Tsinghua Chang Gung Hospital

OTHER

NCT06750783 - The Effects of Xuezhikang and Atorvastatin on Lipid in Patients With Dyslipidemia and Prediabetes | Biotech Hunter | Biotech Hunter